Bhivandkar, S and Sarfraz, Z and Jain, L and Bachu, A and Malo, PK and Hsu, M and Ayub, S and Poudel, L and Kumar, H and Loh, H and Tazin, F and Ahmed, S and Suzuki, J (2024) Therapeutic Potential of Buprenorphine in Depression: A Meta-Analysis of Current Evidence. In: Journal of Clinical Medicine Research, 16 (2-3). pp. 46-55.
|
PDF
jou_cli_med_res_16_3_2024.pdf - Published Version Download (2MB) | Preview |
Abstract
Background: Emerging research indicates buprenorphine, used in management of opioid use disorder, has attracted interest for its potential in treating a variety of psychiatric conditions. This metaanalysis aimed to determine the efficacy of buprenorphine in treating symptoms of depression. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, a search was conducted of several databases until April 25, 2022, for English language articles related to buprenorphine and its use in treating various mental health conditions. Standardized mean differences (SMDs) and its 95 confidence intervals (CIs) were reported for the Hamilton Rating Scale for Depression (HAM-D) and the Montgomery-Asberg Depression Rating Scale (MADRS) scores. Statistical analyses were performed using Cochrane RevMan 5. Results: Of the 1,347 identified studies, six clinical trials were included. MADRS-10 least square mean difference (LSMD) intergroup assessment favored buprenorphine over placebo, but it lacked statistical significance. Similarly, MADRS scores as well as HAM-D inter-group assessment were in favor of buprenorphine, however, were not statistically significant. These findings suggest a potential therapeutic role for buprenorphine in treating depression, albeit with caution due to the observed lack of statistical significance and the potential for confounding factors. Conclusions: Preliminary evidence suggests potential efficacy of buprenorphine at lower doses in improving improving outcomes specifically related to depression. However, due to limitations in statistical significance and possible confounding factors, entail cautious interpretation. Further rigorous research is needed to investigate the long-term effects, optimal dosing, and determine the role of adjuvant drug therapy. © 2024 The authors | Journal compilation. J Clin Med Res and Elmer Press Inc� | www.jocmr.org This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. All Rights Reserved.
| Item Type: | Journal Article |
|---|---|
| Publication: | Journal of Clinical Medicine Research |
| Publisher: | Elmer Press |
| Additional Information: | The copyright for this article belongs to authors. |
| Department/Centre: | Autonomous Societies / Centres > Centre for Brain Research |
| Date Deposited: | 30 Aug 2024 11:01 |
| Last Modified: | 30 Aug 2024 11:01 |
| URI: | http://eprints.iisc.ac.in/id/eprint/84908 |
Actions (login required)
 |
View Item |
